- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00674960
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.
Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.
It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4V 1L5
- The Centre for Incurable Diseases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- People with Pick's Disease
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
|
Far Infrared Radiation (5μm to 20μm wavelength).
Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Therapy for FTD patients
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rehabilitation of FTD Patients
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Dementia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
Other Study ID Numbers
- GAAD-FD-CTP1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pick Disease of the Brain
-
National Eye Institute (NEI)CompletedNiemann Pick DiseasesUnited States, United Kingdom
-
Mandos LLCTerminatedNiemann-Pick Disease, Type CCosta Rica
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownNiemann-Pick Disease, Type C1China
-
ActelionCompleted
-
Vtesse, LLC, a Mallinckrodt Pharmaceuticals CompanyWithdrawnNiemann-Pick Disease, Type C
-
Mandos LLCCompletedNiemann-Pick Disease, Type CUnited States, Australia, United Kingdom, Germany, France, New Zealand, Singapore, Spain, Turkey
-
National Institute of Neurological Disorders and...CompletedBrain Neoplasm | Alzheimer's Disease | Niemann Pick DiseaseUnited States
-
Cyclo Therapeutics, Inc.RecruitingNiemann-Pick Disease, Type C1United States, Spain, Israel, Taiwan, Brazil, Germany, Australia, Poland, Turkey, Italy, United Kingdom
-
Eunice Kennedy Shriver National Institute of Child...TerminatedNiemann-Pick Disease, Type C1United States
-
Cyclo Therapeutics, Inc.CompletedNiemann-Pick Disease, Type C1Israel, Sweden, United Kingdom
Clinical Trials on Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
-
GAAD Medical Research Institute Inc.UnknownAmyotrophic Lateral SclerosisCanada
-
GAAD Medical Research Institute Inc.UnknownMultiple SclerosisCanada
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.UnknownParkinson's DiseaseCanada
-
GAAD Medical Research Institute Inc.UnknownHuntington DiseaseCanada
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.Unknown
-
GAAD Medical Research Institute Inc.Unknown
-
National Taiwan University HospitalChung Shan Medical UniversityCompleted